Boston Scientific Corporation (BSX)
Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
Boston Scientific: Poised To Rebound With The Healthcare Sector, But When?
Boston Scientific Corporation is a leading medtech innovator facing recent share price underperformance due to market share erosion in electrophysiology and sector-wide sentiment shifts. Despite competitive pressures, BSX maintains strong leadership in PFA, with Watchman and neuromodulation as promising growth drivers and a robust pipeline supported by strategic M&A. Management has improved operating and net margins, reduced short-term debt, and achieved ROIC above WACC, signaling efficient capital allocation and resilience despite slowing revenue growth.
BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical vs Boston Scientific: Which Stock Is the Better Buy Post Q1?
Intuitive Surgical's strong Q1 results, rising procedures, and raised outlook highlight accelerating growth, while Boston Scientific faces headwinds and tempered guidance.
Boston Scientific Just Slashed Guidance and Wall Street Followed. Is the Pullback a Buying Opportunity?
Boston Scientific (NYSE:BSX | BSX Price Prediction) stock has taken a beating in 2026 after management cut full-year guidance on Wednesday.
Cwm LLC Has $3.49 Million Stock Holdings in Boston Scientific Corporation $BSX
Cwm LLC reduced its position in shares of Boston Scientific Corporation (NYSE: BSX) by 22.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,604 shares of the medical equipment provider's stock after selling 10,695 shares during the
Stock Market Today, April 22: Boston Scientific Jumps After Q1 Earnings Beat Resets Growth Expectations
Expand NYSE: BSX Boston Scientific Today's Change (8.99%) $5.35 Current Price $64.87 Key Data Points Market Cap $88B Day's Range $61.78 - $65.32 52wk Range $59.38 - $109.50 Volume 40M Avg Vol 17M Gross Margin 65.04% Boston Scientific (BSX +8.99%), a medical device developer, closed Wednesday at $64.87, up 8.99%. The stock is jumping after a Q1 earnings beat paired with lowered 2026 guidance.
Boston Scientific Corporation (BSX) Q1 2026 Earnings Call Transcript
Boston Scientific Corporation (BSX) Q1 2026 Earnings Call Transcript
BSX Q1 Earnings Match, '26 View Down, Stock Gains in Premarket
Boston Scientific meets Q1 EPS estimates, posts 11.6% revenue growth and beats sales estimates, but cuts 2026 outlook; shares still climb in premarket trading.
Boston Scientific (BSX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
